

Zirconium-89 PET Imaging Agent for Cancer

Summary

This technology is a new generation of rationally designed chelating agents that improve the complexation of Zirconium-89 for PET imaging of cancers.

NIH Reference Number

E-111-2013

Product Type

- Diagnostics
- Research Tools

Keywords

- PET
- imaging agent
- zirconium-89

Collaboration Opportunity

This invention is available for licensing and co-development.

Contact

Jaime Greene
NCLTTC

greenejaime@mail.nih.gov (link sends e-mail)

Description of Technology

Researchers at the NCI Radiation Oncology Branch and NIH CIT Center for Molecular Modeling developed a tetrahydroxamate chelation technology that provides a more-stable Zr-89 complex as an immuno-PET cancer imaging agent. In either the linear or the macrocyclic form, the tetrahydroxamate complexes exhibit greater stability as chelating agents compared to Zr-89 complexed to the siderophore desferrioxamine B (DFB), a trihydroxamate, which represents the current state of the art chemistry and the agent currently in clinical use.

In the Zr-89-DFB imaging agents, Zr-89 dissociates from the chelate, resulting in an increasing radioisotope accumulation in the bone 2-3 days after injection. *In vitro* studies demonstrate the tetrahydroxamate-chelated Zr-89 remained kinetically inert for seven or more days, thereby reducing the amount of Zr-89 that is released compared to the

complex containing DFB.

Potential Commercial Applications

• PET imaging, especially for cancer and in particular Immuno-PET imaging

Competitive Advantages

High stability with low toxicity

Inventor(s)

Francois Guerard (NCI), Yong Sok Lee (CIT), Martin Brechbiel Brechbiel (NCI)

Development Stage

• Prototype

Publications

Guerard F, et al. [PMID 23250287]

Guerard F, et al. [PMID 2470517]

Patent Status

• U.S. Patent Filed: U.S. Patent Application Number 61/779,016, Filed 13 Mar 2013

• Foreign Filed: EP - Patent Application 14779019

Related Technologies

- E-194-2007
- E-226-2006
- E-067-1990

Therapeutic Area

• Cancer/Neoplasm

Updated

Wednesday, January 25, 2023

Source URL:https://techtransfer.cancer.gov/availabletechnologies/e-111-2013